Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Augmentin XR Will Be Available In Mid-October, Priced At $9 Per Day

Executive Summary

GlaxoSmithKline will launch its latest addition to the Augmentin family of products in mid-October following FDA's Sept. 25 approval of Augmentin XR

You may also be interested in...



GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth

GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions

GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth

GSK hopes that it can hold on to more than half of its Augmentin franchise with the XR and ES line extensions

Geneva Generic Augmentin Distribution Limited To Warehousing Drug Chains

Drug wholesalers, independent pharmacists and hospital group purchasing organizations are protesting Geneva Pharmaceuticals' decision to directly sell its generic version of GlaxoSmithKline's Augmentin (amoxicillin/clavulanate) only to drug store chains with their own warehouses

Related Content

UsernamePublicRestriction

Register

PS040543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel